NATIONAL HEMOPHILIA FOUNDATION PETITIONS COURT
NATIONAL HEMOPHILIA FOUNDATION PETITIONS COURT NEW YORK, Nov. 21 /PRNewswire/ -- The National Hemophilia Foundation
(NHF), in a move it describes as, "in the interest of safeguarding the medical care of the country's 20,000 people with hemophilia," has petitioned the court to intervene in a recent motion by Rhone-Poulenc- Rorer, Inc. (RPR) for a preliminary injunction that would prevent Baxter International (Baxter) from manufacturing and selling monoclonal factor VIII. The RPR motion, filed in the U.S. District Court for the District of Delaware, is part of an overall action (Scripps Clinic and Research Foundation and Rorer Group Inc. v. Baxter Travenol Laboratories, Inc. Docket No. 87-140 (CMW)) regarding a patent infringement lawsuit pending since 1987.
"NHF's action today is necessitated by our concern for the welfare of people with hemophilia, which must come before all other concerns," said NHF President David B. Walters, Esq. NHF Executive Director Alan P. Brownstein added, "While NHF remains neutral regarding the validity of the patent dispute, we are asking for intervention to ensure that there is no disruption in the supply of clotting factor, which is essential to the health and well-being of people with hemophilia." Hemophilia A is a blood disorder characterized by a deficiency of a blood protein known as factor VIII, which is important to the clotting process. It is the most common form of hemophilia representing 18,000 of the 20,000 people with hemophilia in the United States. NHF is the only national voluntary health agency dedicated to serving the needs of Americans with hemophilia and other bleeding disorders. NHF's action is designed to persuade the court, in ruling on the preliminary injunction application, to guarantee that the supply of clotting factor to people with hemophilia is not disturbed. NHF is neutral with regard to the merits of this commercial patent litigation. According to NHF's Associate Medical Director, Dr. Craig M. Kessler, the preliminary injunction could have far-reaching effects. "Such legal disputes could increase the cost of care," he said. The World Federation of Hemophilia, representing 70 countries, submitted an affidavit in support of NHF's motion to intervene. Charles J. Carman, president of the Montreal-based Federation said, "it would compromise the health care interests of people with hemophilia throughout the world if there were any disruption of the current supply of viral attenuated factor VIII concentrate." NHF is represented by the Livingston, N.J. law firm of Genova, Burns & Schott (Angelo J. Genova and James Burns, Esq.). No hearing date has yet been set by the court on the NHF's application. -0- 11/21/91 /CONTACT: Alan P. Brownstein of NHF, 212-219-8180/ CO: National Hemophilia Foundation ST: New York IN: HEA SU: JT -- NY008 -- 5709 11/21/91 08:30 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 21, 1991|
|Previous Article:||COMPUTER PRODUCTS, INC. TO ACQUIRE HEURIKON CORPORATION|
|Next Article:||ANACOMP INC. REPORTS FOURTH QUARTER AND 1991 YEAR-END RESULTS|